Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1

Conditions

Sarcoma 160Glioblastoma 86Gliosarcoma 79Brain Neoplasms 52Central Nervous System Neoplasms 47Osteosarcoma 43Astrocytoma 40Sarcoma, Ewing 39Neoplasm Metastasis 37Melanoma 35Rhabdomyosarcoma 34Neoplasms 34Ovarian Neoplasms 33Glioma 32Neuroblastoma 30Breast Neoplasms 30Oligodendroglioma 29Lymphoma 28Recurrence 27Colorectal Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Dendritic Cell Sarcoma, Interdigitating 22Stomach Neoplasms 21Lymphoma, Non-Hodgkin 21Gastrointestinal Stromal Tumors 20Carcinoma, Renal Cell 19Sarcoma, Synovial 18Pancreatic Neoplasms 18Lymphoma, Follicular 18Neurofibrosarcoma 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Cancer × Sarcoma × Clear all
NCT05154630 2024-01-18

Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Terminated
8 enrolled
Sarcoma

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡